Vanda Pharmaceuticals Inc VNDA.OQ VNDA.O is expected to show a rise in quarterly revenue when it reports results on February 5 (estimated) for the period ending December 31 2024
The Washington Washington Dc-based company is expected to report a 15.4% increase in revenue to $52.248 million from $45.27 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vanda Pharmaceuticals Inc is for a loss of 11 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $9.25, above its last closing price of $4.41.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.16 | -0.16 | -0.09 | Beat | 44.9 |
Jun. 30 2024 | -0.21 | -0.21 | -0.08 | Beat | 61.9 |
-0.07 | | ||||
Dec. 31 2023 | -0.09 | -0.09 | -0.04 | Beat | 55.6 |
Sep. 30 2023 | -0.04 | -0.04 | 0.00 | Beat | 100 |
Jun. 30 2023 | -0.13 | -0.13 | 0.03 | Beat | 123.1 |
Dec. 31 2022 | 0.08 | 0.08 | 0.12 | Beat | 50 |
This summary was machine generated February 3 at 12:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。